Deep brain stimulation (DBS) is more effective at easing nonmotor symptoms and improving life quality for people with the postural instability and gait disturbance (PIGD) subtype of Parkinson’s disease than for those with the tremor-dominant (TD) subtype, a study showed. While previous studies have suggested different effects of…
People with Parkinson’s disease have a nearly twofold higher risk of developing osteoporosis, a chronic condition marked by increased bone fragility, than healthy people, a study showed. Besides identifying for the first time Parkinson’s as an independent risk factor for osteoporosis, the researchers found five genes with diagnostic and…
Scientists have identified potential biomarkers for the early detection of Parkinson’s disease in certain people carrying a common disease mutation. Specifically, they found that a combination of four small RNA molecules, called microRNAs (miRNAs), in the blood may help predict disease onset in people who carry a Parkinson’s-associated LRRK2…
Suppressing the activity of carnitine palmitoyl-transferase 1 (CPT1) — a key enzyme in the metabolism of fatty molecules — led to reductions in motor and non-motor symptoms in two mouse models of Parkinson’s disease, a new study shows. These benefits were associated with a normalization of blood sugar, or…
Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were…
ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with standard oral therapy in people with advanced Parkinson’s disease. Those are the results of a randomized Phase 3 clinical trial testing the experimental formulation in more than…
The small molecule anle138b, an experimental therapy for Parkinson’s disease, was shown in a study to bind to lipidic (fat) fibrils in alpha-synuclein protein clumps, suggesting it could also offer a new diagnostic approach for the disease. “The promising drug candidate anle138b … binds to lipidic alpha-synuclein structures. The drug…
Get regular updates to your inbox.